Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for GRFS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2011. Start Trial.
Date Value
June 30, 2026 -337.83M
March 31, 2026 -152.09M
December 31, 2025 -87.93M
September 30, 2025 -169.10M
June 30, 2025 -201.72M
March 31, 2025 -140.67M
December 31, 2024 -36.69M
September 30, 2024 -1.688B
June 30, 2024 64.36M
March 31, 2024 180.00M
December 31, 2023 40.67M
September 30, 2023 -88.37M
June 30, 2023
March 31, 2023
December 31, 2022
September 30, 2022
June 30, 2022
March 31, 2022
December 31, 2021
September 30, 2021
June 30, 2021
March 31, 2021 203.39M
December 31, 2020 -167.30M
September 30, 2020 -49.79M
June 30, 2020 -77.27M
Date Value
March 31, 2020 -121.23M
December 31, 2019 -107.48M
September 30, 2019 -38.16M
June 30, 2019 -168.48M
March 31, 2019 -62.85M
December 31, 2018 273.91M
September 30, 2018 99.52M
June 30, 2018 -181.53M
March 31, 2018 -15.58M
December 31, 2017 -37.79M
September 30, 2017 54.96M
June 30, 2017 -68.62M
March 31, 2017 1.669B
December 31, 2016 -148.83M
September 30, 2016 -34.94M
June 30, 2016 -121.11M
March 31, 2016 -59.68M
December 31, 2015 -17.71M
September 30, 2015 1.154M
June 30, 2015 -118.40M
March 31, 2015 -45.84M
December 31, 2014 -156.60M
September 30, 2014 -69.66M
June 30, 2014 -184.75M
March 31, 2014 1.527B

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
argenx SE --
Evaxion AS --
Autolus Therapeutics Plc -2.144M
Pharma Mar SA -0.0493M
Oryzon Genomics SA --